An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Inclusion Criteria: * Male and female participants between the ages of 18 and 65 years * History of orthotopic liver transplantation less than 10 years before the Screening visit but no sooner than 6 months before Day 1 * Taking a stable immunosuppressant regimen based on either tacrolimus or cyclosporine without substantial dose changes over the past 3 months * Naive to pegylated interferon/ribavirin treatment or experienced with pegylated interferon/ribavirin prior to transplantation with relapse, partial, or null response Exclusion Criteria: * Documented cirrhosis after liver transplantation * Ascites or hepatic encephalopathy within 6 months before Screening * Retransplantation for recurrent hepatitis C * Treatment for hepatitis C post liver transplantation * History within the past 3 months of: rejection within 3 months or greater than (\>) 1 rejection within 12 months * Current treatment with sirolimus or methylprednisolone. Low dose prednisone use (\<5 milligram per day) is permitted * History within 3 months of any bacterial infection requiring \>1 week of intravenous antibiotics, cytomegalovirus viremia or cytomegalovirus infection with end-organ involvement, fungal disease (except cutaneous and mild oral thrush) * History of post transplant lymphoproliferative disease * Acceptable laboratory values at Screening as specified in the protocol * Positive for human immunodeficiency virus 1/2 (HIV1/2) enzyme immunoassay (EIA) antibody screen or Hepatitis B deoxyribonucleic acid (DNA) or Hepatitis B surface antigen * History of hepatocellular carcinoma with high risk of recurrence * Any other cause of liver disease deemed clinically significant by the investigator in addition to hepatitis C * Autoimmune-mediated disease * History of acute pancreatitis within 5 years before the Screening visit * Prior treatment with an hepatitis C virus (HCV) protease inhibitor